NEW YORK, July 7, 2014 /PRNewswire/ --Advanced Cell Technology, Inc. (OTCQB: ACTC) is a biotechnology company focused on developing and commercializing human pluripotent stem cell technology in the field of regenerative medicine. The company is currently conducting clinical trials for treating dry age-related macular degeneration (AMD) and Stargardt's macular degeneration (SMD), as well as several clinical and preclinical programs for other ocular therapies. Outside of ophthalmology, ACTC also has a preclinical development pipeline focused on autoimmune diseases, inflammatory diseases and wound healing. The company's intellectual property portfolio includes pluripotent human embryonic stem cells (hESCs), induced pluripotent stem cells (iPSCs), and other cell therapy research programs. As the worldwide population has continued to age, so too has the need for regenerative medicine. In fact, by 2050, the number of people in the world over the age of 65 is expected to rise to 1.5 billion nearly triple the amount today. Unsurprisingly, as this demographic shift occurs over the next 35 years, health care expenditures are projected to increase rapidly as well. For example, in the US, the share of GDP devoted to healthcare is estimated to reach 34% by 2040 from about 18% just a few years ago. Considering the majority … Continue reading →

SAN FRANCISCO, July 8, 2014 /PRNewswire-iReach/ -- Cyto Wave Technologies Inc. (the "Company") (OTCQB: CWAV) announced today that it entered into an exclusive letter of intent ("LOI") with the University of California, San Francisco ("UCSF") in regards to the exclusive global licensing of a medical stereotactic device (the "UCSF Device") which the Company believes has the potential to revolutionize the delivery of stem cells into the human brain and enhance the efficacy of a wide range of stem cell therapeutics. As part of the Company's strategy to develop and commercialize innovative medical device applications, beyond stem cells, the platform technology of the UCSF Device can also enable the delivery of cellular therapeutics, gene therapies, and traditional drug infusions into the human brain. The Stem Cell industry is one of the fastest growing and most compelling areas in medicine with numerous companies and research institutions spending hundreds of millions of dollars per year on the development of new therapies and devices. The Company believes that the UCSF Device could become the preferred tool for the deployment of stem cells into the human brain for any company or clinician conducting clinical trials and providing experimental treatment in this field. Therefore, the use … Continue reading →

By Marcus Johnson Researchers at Brown University have found that adipose-derived human stem cells (ASCs) might be highly resistant to methotrexate (MTX), a common chemotherapy drug. ASCs can ultimately become bone and other vital tissues throughout the body, which could be key for researchers looking to protect bone tissue from the damage caused by MTX treatment. MTX, which is used to treat a number of different cancers including acute lymphoblastic leukemia, causes the loss of bone density and has an adverse effect on bone marrow derived stem cells. Kids undergo chemotherapy at such an important time when they should be growing, but instead they are introduced to this very harsh environment where bone cells are damaged with these drugs, said Olivia Beane, a Brown University graduate student in the Center for Biomedical Engineering and lead author of the study. That leads to major long-term side effects including osteoporosis and bone defects. If we found a stem cell that was resistant to the chemotherapeutic agent and could promote bone growth by becoming bone itself, then maybe they wouldnt have these issues. Beane examined how MTX affects stem cells and certain tissues in the body and said that the resistance of certain … Continue reading →